TRNSPLNT is discussion list serves as an open forum for discussing, and learning about, current issues affecting the practice of transplantation and organ donation.
January - Rezulin is approved by the FDA to treat Type II diabetes.
November - The FDA issues a warning about Rezulin (troglitazone). Recommended prescribing information is changed by the drug's manufacturer; new warning label information is added.
December - Approximately 150 adverse events associated with Rezulin have been reported to the FDA.
1998
June - The FDA and Rezulin manufacturer Parke-Davis agree to again tighten restrictions on the use of Rezulin.
July - Parke-Davis sends a letter to heathcare professionals warning to test for liver abnormalities and updating them on the changes in recommended use.